Saturday, June 27, 2026

#GLP-1

8 articles

Novo Nordisk Surges 24.9% in a Month as AI-Driven Restructuring Revalues the Stock

Stock Performance

Novo Nordisk Surges 24.9% in a Month as AI-Driven Restructuring Revalues the Stock

Salvado•Jun 27, 2026

Novo Nordisk Surges 24.9% in 30 Days After Q1 Beat, Bets on AI Partners Over In-House R&D

Novo Nordisk Surges 24.9% in 30 Days After Q1 Beat, Bets on AI Partners Over In-House R&D

Salvado•Jun 9, 2026

Novo Nordisk Stock Up 24.9% in 30 Days as AI Restructuring Sharpens GLP-1 Focus

Healthcare Equities

Novo Nordisk Stock Up 24.9% in 30 Days as AI Restructuring Sharpens GLP-1 Focus

Salvado•Jun 5, 2026

Novo Nordisk's 24.9% Rally Bets on AI-Driven Pipeline Over In-House Biology

Biotech Equities

Novo Nordisk's 24.9% Rally Bets on AI-Driven Pipeline Over In-House Biology

Salvado•May 31, 2026

Novo Nordisk Jumps 24.9% in 30 Days as AI Drug Pipelines Win Market Confidence

Pharma/Biotech Stocks

Novo Nordisk Jumps 24.9% in 30 Days as AI Drug Pipelines Win Market Confidence

Salvado•May 27, 2026

Novo Nordisk Surges 25% in 30 Days as Market Rewards AI-Driven R&D Overhaul

Pharma Earnings & Stock Performance

Novo Nordisk Surges 25% in 30 Days as Market Rewards AI-Driven R&D Overhaul

Salvado•May 18, 2026

FDA Moves to Ban Compounded GLP-1 Drugs, Threatening TomorrowsRx Business Model

Healthcare & Pharma

FDA Moves to Ban Compounded GLP-1 Drugs, Threatening TomorrowsRx Business Model

ViaNews Editorial Team (Markets)•Feb 21, 2026

Pfizer Eyes GLP-1 Market Entry by 2028: What the Metsera Deal Means for Investors

Pharmaceutical Sector

Pfizer Eyes GLP-1 Market Entry by 2028: What the Metsera Deal Means for Investors

ViaNews Editorial Team (Markets)•Feb 18, 2026